A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD

CONCLUSIONS: Treatment with 400- but not 600-mg/day SPN-812 resulted in statistically significant improvement in the primary endpoint. The negative result seen in the 600-mg/day SPN-812 group was likely due to an unusually high placebo response. Safety data were consistent across all doses in the SPN-812 trials.PMID:34092822 | PMC:PMC8146561

Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Azmi Nasser Tesfaye Liranso Toyin Adewole Nicholas Fry Joseph T Hull Fatima Chowdhry Gregory D Busse Zare Melyan Andrew J Cutler Robert L Findling Stefan Schwabe Source Type: research